Terns Pharmaceuticals (TERN) Stock Surges Amid Analyst Buy

In the quest to outperform the broader market, investors are continually seeking stocks with strong growth potential. Making informed choices can significantly enhance wealth, and Terns Pharmaceuticals Inc (NASDAQ: TERN) has recently attracted attention. On November 6, 2025, TERN closed at $18.19, up 4.36% from the previous close of $17.43. The stock traded 4.37 million shares during the session, reaching an intraday high of $18.60 and a low of $16.83.

Financial Ratios

Analyzing TERN’s financial ratios offers insight into the company’s liquidity and stability. For the most recent quarter, the Quick Ratio and Current Ratio were both 24.70, while the Debt-to-Equity ratio and Long-Term Debt/Equity ratio were at 0.00. On October 15, 2025, Truist initiated coverage on TERN with a Buy rating and a target price of $20, highlighting confidence in the company’s growth prospects.

Insider Activity

Insider activity has been notable and provides signals about management’s outlook. On November 4, 2025, Jill M. Quigley sold 24,520 shares at $18 each, reducing her holdings to zero, while also purchasing the same number of shares for $344,016. Earlier, on October 1, 2025, Emil Kuriakose, the company’s Chief Medical Officer, sold 944 shares at $7.85, leaving him with 51,520 shares. These transactions suggest differing insider strategies amid a volatile market environment.

Valuation and Stock Metrics

From a valuation perspective, TERN has a market capitalization of approximately $1.59 billion and an enterprise value of $1.21 billion. Over the past 52 weeks, the stock reached a high of $18.75 and a low of $1.87. Its monthly Beta is -0.23, reflecting relatively low correlation with broader market swings. The 50-day moving average stands at 118.58%, and the 200-day moving average is 254.94%, indicating recent strong upward momentum.

Shares and Ownership

TERN has an average trading volume of 2.02 million shares per day over the past three months and 6.62 million shares per day over the past ten days. Out of 87.47 million outstanding shares, 69.63 million are floating. Insiders own about 20.43% of the company, while institutions hold 83.32%. The short interest stands at 10,361,211 shares, representing 11.84% of the float, highlighting notable short-selling activity.

Earnings Estimates

Earnings projections for TERN are mixed. Nine analysts currently track the stock, estimating a next-quarter EPS of -$0.31, with a range of -$0.38 to -$0.27. For the fiscal current year, EPS is forecasted between -$1.04 and -$1.25, averaging -$1.13. Looking ahead to the following year, EPS is projected at -$1.24, with a range of -$0.81 to -$1.49.

Outlook

With growing analyst coverage, significant insider activity, and rising stock prices, Terns Pharmaceuticals remains a company to watch in the pharmaceutical sector. Investors are closely monitoring its financial health, stock movements, and market trends to assess potential investment opportunities.